Advancing liquid biopsy through precise EV enrichment & multiomic biomarker discovery
One platform. Thousands of datapoints. Multi-organ insight from a single sample.
Multiomic and multiparametric immunoassays for early diagnostics and disease staging in oncology, neurology, inflammation, autoimmune, metabolic and other diseases
Start a ProjectThe Missing Context in Liquid Biopsy
The Problem
All tissues release biomarkers into circulation—but their origin is lost. Blood contains a complex mixture of signals from across the body. When a biomarker is detected, its tissue or organ of origin is often unknown.
The exoBAMS™ Solution
Extracellular vesicles (EVs) carry the molecular identity of their tissue of origin. exoBAMS™ selectively captures EV populations using origin-specific surface markers—enabling attribution of molecular signals to specific tissues and cell types.
Technology
exoBAMS™ Multiomic Platform
A unified platform delivering higher resolution biological insight from a single sample.
Integrated Multiomic Signal
Capture metabolites, lipids, peptides, proteins, and glycans in a single readout
Single Analytical Platform
MALDI-MS enables streamlined, high-throughput analysis
Simplified Workflow
Direct detection with minimal sample processing
High-Density Data Output
Thousands of measurable molecular datapoints per sample
Multi-Organ Insight
Profile multiple tissues and cell types from a single blood sample
Traditional EV isolation methods capture everything. We capture what matters.
BAMS™ and exoBAMS™ are protected by US Patents 12,467,930, 12,019,070, 11,913,964, 11,639,938, 11,391,729, 11,131,674, 10,451,631, 10,101,336 and 9,618,520.
Other US and international patents pending
STANDARD BULK ISOLATION
Current EV enrichment methods isolate multiple populations and clutter targets with non-specific protein contamination
exoBAMS™ TARGETED CAPTURE
Immunoaffinity-based capture methods isolate precise EV populations for developing actionable disease signatures
exoBAMS™: An Integrated Workflow
exoBAMS™ Reagents: Precision Immunocapture
exoBAMS™ reagents are designed for the immunocapture (selective enrichment) of disease-specific exosomes and other EV types from biofluids and conditioned media. This targeted approach dramatically improves the signal-to-noise ratio, ensuring that subsequent analyses focus on the most relevant molecular information.
Data Acquisition: Maximizing Information Content
Proprietary methods of processing and measuring the captured exosome/EV populations have the key objective to maximize the information content derived from these small, complex vesicles. This involves sophisticated handling techniques that preserve the integrity of the captured material to detect a wide array of molecular components (proteins, metabolites, lipids) with extreme sensitivity and resolution.
Data Analytics: Molecular Signatures
Finally, the measurement data generated from multiple exoBAMS™ experiments are fed into powerful data analytics engines. This analysis can identify patterns and relationships within massive datasets. The goal is to create "molecular signatures" of diseases. These are unique combinations of different molecular features that specifically and reliably characterize a disease state, its progression, or even response to treatment. By comparing unknown samples against these established signatures, exoBAMS™ technology can provide valuable diagnostic or prognostic insights.
Disease Signatures
High-content molecular profiling of plasma EVs reveals disease- and cell-type–specific molecular signatures from a single milliliter of blood.
These highlighted examples demonstrate the baseline precision of the exoBAMS™ workflow for clinical research achieving clear separation using only fundamental Principal Component Analysis (PCA). To unlock advanced supervised learning models, access our full, unpublished validation data, and apply this proprietary resolution to your own biomarker discovery—contact us to explore a custom assay partnership.
ALZHEIMER’S DISEASE
Independent cell populations reveal consistent disease separation
PARKINSON’S DISEASE
Independent neuronal and glial EV populations reveal Parkinson's-associated signatures
Products
- Custom EV Reference Materials: ADX-RM-CUSTOM
Disease-specific, stage-specific and cell-type–specific EV populations prepared using exoBAMS™ enrichment technology.
Available upon request for assay development, biomarker discovery, analytical validation, and translational researchResearch reference materials are prepared on a project-specific basis.
Contact Adeptrix to discuss availability, specifications, sample volumes, and customization options.
Services
Transform Biofluids into Biological Insight
Adeptrix provides custom exoBAMS™ assay development and bioanalytical services for biomarker discovery, disease signature analysis, and translational research.
Using targeted extracellular vesicle (EV) enrichment and high-content molecular profiling, exoBAMS™ enables researchers to access disease-relevant biology that is often obscured within conventional liquid biopsy datasets.
Whether your goal is to develop a new EV capture assay, discover novel biomarkers, or uncover disease-associated molecular signatures, our team can design a workflow tailored to your research objectives.
CUSTOM ASSAY DEVELOPMENT
Access new disease-, tissue-, or cell-specific EV populations
Every disease produces unique extracellular vesicle populations. When existing assays do not address your research question, Adeptrix can develop custom enrichment reagents and workflows targeting specific EV populations of interest.
BIOMARKER DISCOVERY
Identify molecular features associated with disease state, progression, and treatment response
Targeted EV enrichment enables access to highly specific molecular cargo that may be difficult or impossible to detect in unfractionated plasma or serum. Using exoBAMS™, researchers can identify candidate biomarkers associated with disease status, progression, treatment response, and biological mechanisms.
DISEASE SIGNATURE ANALYSIS
Generate and interpret high-content EV datasets for cohort stratification and biological insight
The same platform used to generate the disease signatures featured throughout this website can be applied to your samples to identify disease-associated molecular patterns and cohort-specific biology
Our Collaborative Process
Consultation & Target Strategy
We consult with your team to understand your clinical or research objectives. Whether you are profiling prostate cancer stages, investigating microglial activation in Alzheimer's, or characterizing total exosome output, we select or customize our workflow for your target and species.
High-Fidelity Enrichment
Using the exoBAMS™ platform, our analytical team processes your complex sample matrices (plasma, serum or conditioned media). Our reagents bind specifically to the target EV surface markers, washing away the complex biological background.
Multiomic Profiling and Validation
The highly purified EV fractions are seamlessly transitioned into downstream analysis. We work with you to generate the data you need, whether that involves protein, lipid or metabolomic profiling, or next-generation sequencing (NGS) of exosomal RNA.
Deliverables & Scale-Up
You receive comprehensive, validated data sets and a custom-developed assay protocol optimized for your specific downstream applications, ready for your next phase of research or clinical development.
Why Partner With Us?
- Exclusive Technology Access – Utilize highly specific reagents unavailable anywhere else on the market.
- Liquid Biopsy Expertise – Leverage our team's deep understanding of biomarker discovery and multiomic analysis.
- Accelerated Timelines – Bypass the months of trial-and-error typically associated with optimizing standard EV isolation methods.
- Disease-Specific Focus – Build assays utilizing reagents already validated for complex fields like early-stage cancer detection, brain cell typing, and mixed pathologies.
About Us
PUSHING THE BOUNDARIES OF BIOANALYSIS
To accelerate the development of high-resolution liquid biopsies and advanced diagnostics by providing researchers with unparalleled access to pure, disease-specific exosome and EV populations.
The potential of extracellular vesicles as sources of critical biomarkers for early disease detection and treatment monitoring is clear. However, the true promise of these particles has long been bottlenecked by outdated isolation technologies. Methods that rely on size or density separation inevitably co-isolate massive amounts of non-specific proteins and cellular debris, obscuring the very signals researchers are trying to find. We recognized that the next leap in diagnostics and drug development required a fundamental shift in bioanalytical methodology. It required precision.
Our team of scientists and bioengineers developed the exoBAMS™ (exosome Bead Assisted Mass Spectrometry) platform to solve the purity problem. By utilizing highly specific, cataloged immunoaffinity reagents, we enable the targeted enrichment of distinct exosome subpopulations—whether derived from specific brain cells, distinct tumor types, or broad biofluid populations.
We operate at the intersection of sensitivity, speed, and information content. We are not just a reagent supplier; we are an analytical partner. By integrating our proprietary reagents with our custom assay development services, we empower our partners to extract robust lipidomic, proteomic and transcriptomic data from the most complex sample matrices. From early-stage cancer detection to neurological disease subtyping, we are here to help you isolate the signals that drive clinical innovation.
Partner with us on Custom Pilot Projects
We are currently opening a select number of slots for custom analytical assay pilot projects. By partnering with us, your team gains access to dedicated development resources to build, optimize, and validate an exoBAMS™ assay tailored specifically to your unique R&D goals.
Whether you are looking to profile specific exosome surface markers or streamline your bioanalytical workflows, we can build the exact tool you need to accelerate your pipeline.